LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

Home・Aandelen Lijst・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Gesloten

1.68 3.7

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.5699999999999998

Max

1.6800000000000002

Belangrijke statistieken
By Trading Economics
Inkomsten	13M -43M
Winstmarge	-2,190.837
Werknemers	171
EBITDA	17M -42M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+85.19% upside

Dividenden
By Dow Jones
Volgende Winsten	13 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-1.8M 103M
Vorige openingsprijs	-2.02
Vorige sluitingsprijs	1.68

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

1.43 / 1.6 Steun & Weerstand

Pliant Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 nov 2025, 23:59 UTC

Winsten

Singtel's 1st Half Net Profit Surges

11 nov 2025, 22:23 UTC

Acquisities, Fusies, Overnames

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11 nov 2025, 22:21 UTC

Winsten

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11 nov 2025, 23:52 UTC

Marktinformatie

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11 nov 2025, 23:44 UTC

Winsten

Singtel's 1H Net Profit Surges

11 nov 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11 nov 2025, 23:18 UTC

Winsten

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11 nov 2025, 23:15 UTC

Winsten

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11 nov 2025, 23:14 UTC

Winsten

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11 nov 2025, 23:12 UTC

Winsten

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11 nov 2025, 23:11 UTC

Winsten

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11 nov 2025, 23:10 UTC

Winsten

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11 nov 2025, 23:04 UTC

Marktinformatie

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

11 nov 2025, 21:50 UTC

Marktinformatie

Winsten

Health Care Roundup: Market Talk

11 nov 2025, 21:46 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11 nov 2025, 21:41 UTC

Winsten

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11 nov 2025, 21:40 UTC

Winsten

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11 nov 2025, 21:39 UTC

Winsten

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11 nov 2025, 21:38 UTC

Winsten

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11 nov 2025, 21:38 UTC

Winsten

Aristocrat: Final Dividend 49 Australian Cents/Share

11 nov 2025, 21:37 UTC

Winsten

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11 nov 2025, 21:36 UTC

Winsten

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11 nov 2025, 21:35 UTC

Winsten

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q Adj EPS 79c >ALC

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q Rev $2.61B >ALC.EB

11 nov 2025, 21:35 UTC

Winsten

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11 nov 2025, 21:35 UTC

Winsten

Alcon 3Q EPS 48c >ALC.EB

Peer Vergelijking

Prijswijziging

Pliant Therapeutics Inc Prognose

Koersdoel

By TipRanks

85.19% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3 USD 85.19%

Hoogste 4 USD

Laagste 2 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pliant Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Pliant Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.43 / 1.6Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.